ASCO 2025 – zilo-V adds a patient death to its tox tally
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
ASCO 2025 – Astra seeks a new SERD paradigm
But camizestrant’s use could depend on uptake of monitoring – for now.
ASCO 2025 – Enhertu mounts its first-line charge
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
Harmoni spoils Summit's pre-ASCO splash
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
ASCO 2025 – Trodelvy heads for the front line
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
The first test of Recursion's Exscientia move
The combined company's MALT1 inhibitor has started phase 1.
ASCO 2025 – vepdegestrant matches rival degraders
Any hopes of differentiation could come down to side effects.
